Type / Class
Equity / Common Stock, $0.0001 Par Value Per Share
Shares outstanding
108M
Number of holders
226
Total 13F shares, excl. options
79.5M
Shares change
+11.9M
Total reported value, excl. options
$4.86B
Value change
+$736M
Put/Call ratio
0.56
Number of buys
144
Number of sells
-88
Price
$61.19

Significant Holders of Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share (ITCI) as of Q1 2022

283 filings reported holding ITCI - Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share as of Q1 2022.
Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share (ITCI) has 226 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 79.5M shares of 108M outstanding shares and own 73.79% of the company stock.
Largest 10 shareholders include FMR LLC (11M shares), VANGUARD GROUP INC (7.79M shares), WASATCH ADVISORS INC (7.48M shares), BlackRock Inc. (6.47M shares), WELLINGTON MANAGEMENT GROUP LLP (4.06M shares), Bellevue Group AG (3.43M shares), MARSHALL WACE, LLP (2.52M shares), LORD, ABBETT & CO. LLC (1.98M shares), STATE STREET CORP (1.79M shares), and FRANKLIN RESOURCES INC (1.7M shares).
This table shows the top 226 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
Investor Option Weight % Change % Value $ * Price $ Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.